Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia

Chronic myelogenous leukemia (cml) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to a rapidly fatal cml blast crisis. Until recently, the standard of care included potentially curative...

Full description

Bibliographic Details
Main Authors:	Laneuville, P., Barnett, M.J., Bélanger, R., Couban, S., Forrest, D.L., Roy, D.C., Lipton, J.H.
Format:	Online
Language:	English
Published:	Multimed Inc. 2006
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394607/

id	pubmed-3394607
recordtype	oai_dc
spelling	pubmed-33946072012-07-12 Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia Laneuville, P. Barnett, M.J. Bélanger, R. Couban, S. Forrest, D.L. Roy, D.C. Lipton, J.H. Original Article Chronic myelogenous leukemia (cml) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to a rapidly fatal cml blast crisis. Until recently, the standard of care included potentially curative therapy with allogeneic stem cell transplantation, available only to a minority (about 10%) of patients, or medical therapy with interferon-α with or without cytarabine, which helped to prolong the chronic phase of the disease in a minority of patients. The availability of imatinib mesylate, a selective inhibitor of Bcr/Abl approved by Health Canada in 2001, has profoundly altered the clinical and laboratory management of cml. This change in practice has been reviewed by the Canadian Consensus Group on the Management of Chronic Myelogenous Leukemia and has resulted in a new set of recommendations for the optimal care of cml patients. Multimed Inc. 2006-12 /pmc/articles/PMC3394607/ /pubmed/22792021 Text en 2006 Multimed Inc.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Laneuville, P. Barnett, M.J. Bélanger, R. Couban, S. Forrest, D.L. Roy, D.C. Lipton, J.H.
spellingShingle	Laneuville, P. Barnett, M.J. Bélanger, R. Couban, S. Forrest, D.L. Roy, D.C. Lipton, J.H. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
author_facet	Laneuville, P. Barnett, M.J. Bélanger, R. Couban, S. Forrest, D.L. Roy, D.C. Lipton, J.H.
author_sort	Laneuville, P.
title	Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
title_short	Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
title_full	Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
title_fullStr	Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
title_full_unstemmed	Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
title_sort	recommendations of the canadian consensus group on the management of chronic myeloid leukemia
description	Chronic myelogenous leukemia (cml) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to a rapidly fatal cml blast crisis. Until recently, the standard of care included potentially curative therapy with allogeneic stem cell transplantation, available only to a minority (about 10%) of patients, or medical therapy with interferon-α with or without cytarabine, which helped to prolong the chronic phase of the disease in a minority of patients. The availability of imatinib mesylate, a selective inhibitor of Bcr/Abl approved by Health Canada in 2001, has profoundly altered the clinical and laboratory management of cml. This change in practice has been reviewed by the Canadian Consensus Group on the Management of Chronic Myelogenous Leukemia and has resulted in a new set of recommendations for the optimal care of cml patients.
publisher	Multimed Inc.
publishDate	2006
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394607/
_version_	1611542444427444224

Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia

Similar Items